# Apollo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apollo-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.apollotherapeutics.com
- Total disclosed funding: $400M
- Latest round: Series C (Dec 6, 2023)
- Investors on record: 5

## About

Based in Cambridge, UK, and founded in 2016, Apollo Therapeutics is a biopharmaceutical company that develops therapies for rare diseases. The company's CEO, Dr. Richard Mason, CSO, Dr. Richard Butt, CFO, Jamie Heath, and CBO, Arjun Krishnan. In December 2023, Apollo Therapeutics Limited raised USD 33.5 million in a Series C funding led by Patient Square Capital, with participation from Rock Springs Capital and M&G plc. The series C round of financing values Apollo Therapeutics Limited at GBP 529.72 million post-money. Apollo Therapeutics provides transformative treatments and de-risked pipeline in oncology, major inflammatory disorders and rare disease. The company plans to use the December 2023 funding to support the growth of its programs through clinical development.

## Funding rounds

- Series C, Dec 6, 2023, $33M — Rock Springs Capital, Patient Square Capital, M&G plc
- Series C, Sep 11, 2023, $225M — Rock Springs Capital, Patient Square Capital, M&G plc
- Series B, Jun 16, 2021, $141M — Rock Springs Capital, Qstar Capital, UCL Technology Fund, Patient Square Capital

## Investors

- Rock Springs Capital — Series B, Series C
- Qstar Capital (https://capitalatlas.ai/funds/qstar-capital) — Series B
- UCL Technology Fund (https://capitalatlas.ai/funds/ucl-technology-fund) — Series B
- Patient Square Capital (https://capitalatlas.ai/funds/patient-square-capital) — Series B, Series C
- M&G plc — Series C